Our read is that taking acarbose is well supported for longevity benefits.
✓WELLSUPPORTED
Consensus
95%
broad agreement
Evidence quality
45/100
limited
Risk
Med
monitor
Cost / month
$$
estimated
Effort
Low
time & habit
Abstract
Our read is that acarbose, an FDA-approved drug with a long safety history, is primarily active in the gut and not significantly absorbed systemically.
Experts suggest it blunts post-meal blood sugar spikes, improves insulin sensitivity, and has shown lifespan extension and cardiovascular benefits in animal models, even when started in middle or old age.
The benefits may be linked to lowering glucose and insulin levels, potentially mimicking caloric restriction by blocking starch digestion.
Method
Peter Attia uses 100 mg of acarbose before high-carbohydrate meals to prevent glucose spikes. Bryan Johnson's blood glucose optimization protocol includes Acarbose as part of a broader regimen.
Evidence detail
01Peter Attia states that acarbose is primarily active in the gut and not significantly absorbed systemically (3x).
02Bryan Johnson notes that Acarbose 200 mg daily blunts post-meal blood sugar spikes, improves insulin sensitivity, and has shown lifespan extension and cardiovascular benefits in animal models (1x).
03Peter Attia indicates that canagliflozin blocks post-meal glucose spikes, extends lifespan in mice, and shows preferential effects in males, suggesting a similar mechanism to acarbose (1x).
04Peter Attia suggests acarbose's greater efficacy in male mice may be due to their higher sensitivity to glucose spikes, which acarbose mitigates (2x).
05
Conflict Watch
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Peter Attia claims the benefits of SGLT2 inhibitors and acarbose in ITP studies may relate to glucose kinetics rather than just reduced caloric intake (1x).
06Peter Attia, Andrew Huberman, and David Sinclair collectively state that acarbose started in late middle age is effective for extending lifespan in both sexes, but less so than when started in youth (9x).
07Peter Attia and David Sinclair confirm that acarbose is an FDA-approved drug with a long safety history, making it a candidate for longevity trials (4x).
08Peter Attia believes acarbose likely works by blunting post-meal glucose spikes rather than reducing overall glucose absorption (1x).
09Peter Attia, Andrew Huberman, and David Sinclair note that acarbose, 17-alpha-estradiol, and canagliflozin have shown lifespan extension benefits in mice even when started in middle or old age (9x for acarbose, 4x for all three).
10Peter Attia and Andrew Huberman suggest that lowering glucose and insulin levels may be linked to increased lifespan and could be beneficial for certain forms of dementia (2x).
Caveats
Peter Attia points out that the removal of the pair-fed arm in the ITP study for acarbose prevents understanding how much of the observed effects are due to changes in food consumption or temporal eating patterns (2x). Peter Attia also notes that acarbose has a significant effect in male mice and a small but significant effect in female mice, possibly due to males being more sensitive to high glucose levels (5x).
What would change this verdict
A clearer understanding of acarbose's effects on food consumption and temporal eating patterns, or further research clarifying sex-specific efficacy, would change the verdict.